Gender‐specific differences associated with living donor liver transplantation: A review study

Hanna C. Hermann, Burghard F. Klapp, Gerhard Danzer, Christina Papachristou – 16 December 2009 – Living donor liver transplantation (LDLT) has developed into an important therapeutic option for liver diseases. For living donor kidney transplantation (LDKT), gender‐specific differences have been observed among both donors (two‐thirds being women and one‐third being men) and recipients (two‐thirds being men and one‐third being women). The aim of this study was to determine whether there is a gender disparity for LDLT.

Rapamycin and tacrolimus differentially modulate acute graft‐versus‐host disease in rats after liver transplantation

Guodong Xu, Linyan Wang, Wei Chen, Fei Xue, Xueli Bai, Liang Liang, Xuning Shen, Mangli Zhang, Dajing Xia, Tingbo Liang – 16 December 2009 – Acute graft‐versus‐host disease (aGVHD) is a serious complication of liver transplantation (LTx); it occurs in 1% to 2% of liver allograft recipients. The condition has a poor prognosis and poses major diagnostic and therapeutic challenges. A rat model of aGVHD after LTx has been developed, and a relative decrease in regulatory T (Treg) cells has been shown to be associated with this model.

Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease

Kanthi Yalamanchili, Sherif Saadeh, Göran B. Klintmalm, Linda W. Jennings, Gary L. Davis – 16 December 2009 – Nonalcoholic steatohepatitis (NASH) may account for many cases of cryptogenic cirrhosis. If so, then steatosis might recur after liver transplantation. Two thousand fifty‐two patients underwent primary liver transplantation for chronic liver disease between 1986 and 2004. Serial liver biopsy samples were assessed for steatosis and fibrosis. Two hundred fifty‐seven patients (12%) had a pretransplant diagnosis of cryptogenic cirrhosis (239) or NASH (18).

Raltegravir‐based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus–infected patients after solid organ transplantation

Ana Moreno, María J. Pérez‐Elías, José L. Casado, Jesús Fortún, Rafael Bárcena, Carmen Quereda, Santos del Campo, Carmen Gutiérrez, Oscar Pastor, Javier Nuño, Ana Fernandez, Santiago Moreno – 16 December 2009

Modified pediatric end‐stage liver disease scoring system and pediatric liver transplantation in Brazil

Joao Seda Neto, Eduardo Carone, Renata P. S. Pugliese, Eduardo A. Fonseca, Gilda Porta, Irene Miura, Vera B. Danesi, Teresa C. Guimaraes, Andre L. Godoy, Adriana Porta, Rodrigo Vincenzi, Francisco Carnevale Filho, Mario Kondo, Paulo Chapchap – 15 December 2009 – The Pediatric End‐Stage Liver Disease (PELD) scoring system is a formula developed to provide a continuous numerical assessment of the risk of death in order to allocate livers to children in need of transplantation. The PELD scoring system was introduced in Brazil in July 2006.

Lactoferrin protects against acetaminophen‐induced liver injury in mice

Hao Yin, Linling Cheng, Michael Holt, Numsen Hail, Robert MacLaren, Cynthia Ju – 30 November 2009 – Acetaminophen‐induced liver injury (AILI) is a significant health problem and represents the most frequent cause of drug‐induced liver failure in the United States. The development and implementation of successful therapeutic intervention strategies have been demanding, due to significant limitations associated with the current treatment for AILI. Lactoferrin (Lac), a glycoprotein present in milk, has been demonstrated to possess a multitude of biological functions.

MicroRNA‐30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma

Jian Yao, Linhui Liang, Shenglin Huang, Jie Ding, Ning Tan, Yingjun Zhao, Mingxia Yan, Chao Ge, Zhenfeng Zhang, Taoyang Chen, Dafang Wan, Ming Yao, Jinjun Li, Jianren Gu, Xianghuo He – 30 November 2009 – The pathological relevance and significance of microRNAs (miRNAs) in hepatocarcinogenesis have attracted much attention in recent years; however, little is known about the underlying molecular mechanisms through which miRNAs are involved in the development and progression of hepatocellular carcinoma (HCC).

Subscribe to